Laney D A, Houde M F, Foley A L, Peck D S, Atherton A M, Manwaring L P, Grange D K, Heese B A, Holida M D, Quillin A L, Vinson R, Auray-Blais C, Hopkin R J
School of Medicine, Department of Human Genetics, Emory University, Atlanta, GA.
Division of Laboratory Genetics and Genomics, Mayo Clinic, Rochester, MN.
Genet Med Open. 2024 Sep 10;2:101891. doi: 10.1016/j.gimo.2024.101891. eCollection 2024.
This prospective, longitudinal study was designed to determine the natural history of Fabry disease (FD) in early pediatric patients across the disease spectrum.
In this observational study of children under 5 years of age with variants in the gene, prospective phenotypic and urinary biomarker data were collected annually over 5 years.
The study population included 40 participants (35 male, 5 female) with variants including 15 with classic pathogenic variants (CFD), 6 with nonclassic pathogenic variants (NFD), and 19 with a variant of uncertain significance. The most common first symptoms reported were in participants with CFD and included gastrointestinal symptoms (13/15), heat intolerance (13/15), reduced sweating after previously sweating normally (6/15), and neuropathic pain/uncomfortable feet/hands (3/15). Mapping symptom onset and progression reveals a consistent pattern of frequency and severity occurring in the first years of life and beginning at an average age of 23.4 months (range 11-32 months) in males with CFD. Participants with nonclassic pathogenic variants and variant of uncertain significance did not exhibit consistency in symptom onset or progression during the study period.
This study highlights the onset and pattern of progression of the earliest Fabry-related symptoms in children with CFD.
本前瞻性纵向研究旨在确定疾病谱中早期儿科患者法布里病(FD)的自然病史。
在这项针对5岁以下携带该基因变异儿童的观察性研究中,在5年时间里每年收集前瞻性表型和尿液生物标志物数据。
研究人群包括40名参与者(35名男性,5名女性),携带的变异包括15名携带经典致病变异(CFD)、6名携带非经典致病变异(NFD)以及19名携带意义未明变异。报告的最常见首发症状出现在CFD参与者中,包括胃肠道症状(13/15)、不耐热(13/15)、既往正常出汗后出汗减少(6/15)以及神经性疼痛/足部/手部不适(3/15)。绘制症状发作和进展情况显示,在生命的最初几年出现了频率和严重程度一致的模式,CFD男性患者平均发病年龄为23.4个月(范围11 - 32个月)。非经典致病变异和意义未明变异的参与者在研究期间症状发作或进展情况不一致。
本研究突出了CFD患儿最早出现的法布里病相关症状的发作情况和进展模式。